| 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES |
Active Substance:ACECLOFENAC |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:AMLODIPINE BESILATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:EZETIMIBE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:METHISOPRINOL (INOSINE DIMEPRANOL ACEDOBEN) |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:PREGABALIN |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:TOLPERISONE HYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:TRIMETAZIDINE DIHYDROCHLORIDE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:LISINOPRIL DIHYDRATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|
Active Substance:DABIGATRAN ETEXILATE MESYLATE |
|
3.1
|
Manufacture of Active Substance by Chemical Synthesis
|
| |
| 3.1.1 Manufacture of active substance intermediates |
| 3.1.2 Manufacture of crude active substance |
| 3.1.3 Salt formation / Purification steps: .
|
|
|
3.5
|
General Finishing Steps
|
| |
| 3.5.1 Physical processing steps: .
|
| 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) |
| 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) |
|
|
3.6
|
Quality Control Testing
|
| |
| 3.6.1 Physical / Chemical testing |
| 3.6.2 Microbiological testing excluding sterility testing |
|